Intelgenx Technologies Corp represents values of innovation, integrity, and excellence. With a strong commitment to advancing drug delivery technologies, the company aims to provide improved treatment options to patients worldwide. Intelgenx focuses on developing novel oral films and tablets, utilizing its proprietary VersaFilm® technology. By prioritizing research and development, Intelgenx strives to be at the forefront of the pharmaceutical industry. The company's dedication to quality and collaboration fosters partnerships with renowned pharmaceutical companies, leading to successful product commercialization. Intelgenx's corporate philosophy centers around bringing innovative solutions to market, enhancing patient well-being, and creating value for shareholders.

Intelgenx Technologies Corp is primarily present in Canada, the United States, and Europe. With headquarters in Montreal, Canada, Intelgenx specializes in the development and manufacturing of novel oral thin film drug delivery systems. The company operates its primary production facility in Montreal, where it leverages its proprietary VersaFilm™ technology to provide pharmaceutical solutions to various partners worldwide. Furthermore, Intelgenx has established collaborations with global pharmaceutical companies, expanding its presence and reach across different countries and regions.

Intelgenx Technologies Corp has achieved several significant milestones. The company successfully developed innovative oral thin film delivery technology, which has attracted partnerships with leading global pharmaceutical companies. Moreover, Intelgenx Technologies Corp has secured multiple patents, demonstrating its commitment to intellectual property protection. The company has also gained regulatory approvals for various products in different regions, solidifying its market presence. With a strong focus on research and development, Intelgenx Technologies Corp continues to drive innovation in drug delivery systems, positioning itself as a key player in the pharmaceutical industry.

Founded in 2003, Intelgenx Technologies Corp is a Canadian-based pharmaceutical company that specializes in the development and manufacturing of innovative oral film drug delivery systems. With a focus on enhancing the bioavailability and efficacy of existing drugs, Intelgenx has established itself as a leader in the field. The company utilizes its proprietary VersaFilm™ technology to develop pharmaceutical films that offer improved drug absorption and patient compliance. As an innovative player in the pharmaceutical industry, Intelgenx continues to collaborate with global partners and seek regulatory approvals to commercialize its products. With a strong history of research and development, Intelgenx Technologies Corp is dedicated to advancing drug delivery systems for improved patient outcomes.

The main competitors of Intelgenx Technologies Corp in the market include pharmaceutical companies such as Novartis AG, Pfizer Inc., and Johnson & Johnson. These companies are also involved in the development and commercialization of various drug delivery technologies and products.

Intelgenx Technologies Corp is primarily active in the pharmaceutical industry.

The business model of Intelgenx Technologies Corp revolves around pharmaceuticals and drug delivery systems. Intelgenx is a leading oral drug delivery company that focuses on developing innovative products for the global market. The company specializes in developing novel formulations and delivery technologies, enabling the improved absorption and therapeutic performance of existing drugs. Intelgenx works in collaboration with pharmaceutical partners to develop and commercialize these innovative formulations. By leveraging its proprietary technologies and expertise, Intelgenx aims to enhance patient outcomes and facilitate the delivery of effective therapies through oral drug delivery systems.

Pašreizējais KGV Intelgenx Technologies nevar tikt aprēķināts.

KUV šobrīd Intelgenx Technologies nevar aprēķināt.

AlleAktien kvalitātes vērtējums Intelgenx Technologies ir 6/10.

Pašreiz nevar aprēķināt apgrozījumu Intelgenx Technologies.

Pašlaik peļņa Intelgenx Technologies nevar tikt aprēķināta.

Intelgenx Technologies Corp is a leading company in the development of innovative oral film technologies for targeted drug delivery. The company is headquartered in Montreal, Canada and is listed on the NASDAQ and TSX-V stock exchanges. Its goal is to support the development of safe, reliable, and effective medications through innovative technologies. Intelgenx offers a wide range of products and services to meet customers' specialized medication delivery needs. This includes the development and manufacturing of various formulations such as film strips, capsules, tablets, and granules. The company collaborates closely with other pharmaceutical companies and licenses its technologies based on customer needs to ensure the products meet the highest quality standards. Intelgenx has developed several technology platforms that enable precise and targeted drug delivery, including the Oral-Mucoadhesive Strategy (ORM), Quick Dissolves Films (QDF), Ultra-Rapid Film Technology (URF), and Folate-Targeted PharmaFilm Technology (FTPT). In addition, the company has announced a partnership with RedHill Biopharma Ltd. to develop and market drugs for gastrointestinal diseases, with a focus on the oral delivery of RHB-105 (Talicia) for the treatment of Helicobacter pylori infections. Intelgenx Technologies Corp. has also established a partnership with Chemo Group from Italy to develop and market an Alprazolam oral film technology that ensures faster action in anxiety disorders. Under the leadership of CEO Dr. Horst G. Zerbe, the company has an experienced management team consisting of experts in the fields of pharmacy, medicine, marketing, and finance. Its goal is to become a global leader in the development and manufacturing of oral film technologies that revolutionize the way medications are administered. In conclusion, Intelgenx Technologies Corp is an innovative company specialized in the development of oral film technologies for precise and targeted drug delivery. With its experienced management team, versatile technology platforms, and advanced production facilities, the company has established itself as a leader in this field and aims to position itself as a global market leader.

Intelgenx Technologies izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Intelgenx Technologies vai uzņēmums nedod dividendes.

Intelgenx Technologies ISIN ir US45822R1014.

Intelgenx Technologies WKN ir A0RP0X.

Intelgenx Technologies simbols ir IGX.TO.

Pēdējo 12 mēnešu laikā Intelgenx Technologies maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Intelgenx Technologies plāno maksāt dividendes 0 USD apmērā.

Intelgenx Technologies pašreizējā dividendu rentabilitāte ir .

Intelgenx Technologies maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Intelgenx Technologies pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Intelgenx Technologies tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Intelgenx Technologies apmērā 0 USD, kas tika izmaksāta 20.11.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 20.11.2024..

Pēdējās dividendes izmaksa notika 20.11.2024..

Gadā 2023, Intelgenx Technologies izmaksāja 0 USD dividendes.

Intelgenx Technologies dividendes tiek izmaksātas USD.